Rekah Financial Statements From 2010 to 2024
| REKA Stock | ILA 1,392 9.00 0.64% |
Check Rekah Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rekah Pharmaceutical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Rekah financial statements analysis is a perfect complement when working with Rekah Pharmaceutical Valuation or Volatility modules.
Rekah |
Rekah Pharmaceutical Industry Company Return On Equity Analysis
Rekah Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Rekah Pharmaceutical Return On Equity | 0.0222 |
Most of Rekah Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rekah Pharmaceutical Industry is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Rekah Pharmaceutical Industry has a Return On Equity of 0.0222. This is 100.09% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all Israel stocks is 107.16% lower than that of the firm.
Rekah Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rekah Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Rekah Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rekah Pharmaceutical competition to find correlations between indicators driving Rekah Pharmaceutical's intrinsic value. More Info.Rekah Pharmaceutical Industry is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.94 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Rekah Pharmaceutical Industry is roughly 1.07 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rekah Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rekah Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Rekah Pharmaceutical Financial Statements
Rekah Pharmaceutical stakeholders use historical fundamental indicators, such as Rekah Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Rekah Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Rekah Pharmaceutical's assets and liabilities are reflected in the revenues and expenses on Rekah Pharmaceutical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Rekah Pharmaceutical Industry. Please read more on our technical analysis and fundamental analysis pages.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rekah Stock
Rekah Pharmaceutical financial ratios help investors to determine whether Rekah Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rekah with respect to the benefits of owning Rekah Pharmaceutical security.